Anthony Jarkowski
Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies, Renal cell carcinoma treatment, CAR-T cell therapy research
Most-Cited Works
- → Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing(2010)435 cited
- → Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC(2018)306 cited
- → Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy(2018)263 cited
- → Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer(2018)190 cited
- → Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC)(2014)112 cited
- Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.(2011)
- → Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study(2017)31 cited
- → Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design(2020)28 cited
- → Possible contribution of aprepitant to ifosfamide-induced neurotoxicity(2008)27 cited
- → Response to Sorafenib After Sunitinib‐Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature(2009)26 cited